Next Article in Journal
The Defined TLR3 Agonist, Nexavant, Exhibits Anti-Cancer Efficacy and Potentiates Anti-PD-1 Antibody Therapy by Enhancing Immune Cell Infiltration
Next Article in Special Issue
Adjuvant PD-1 Checkpoint Inhibition in Early Cutaneous Melanoma: Immunological Mode of Action and the Role of Ultraviolet Radiation
Previous Article in Journal
EWSR1::ATF1 Orchestrates the Clear Cell Sarcoma Transcriptome in Human Tumors and a Mouse Genetic Model
Previous Article in Special Issue
Modern Approach to Melanoma Adjuvant Treatment with Anti-PD1 Immune Check Point Inhibitors or BRAF/MEK Targeted Therapy: Multicenter Real-World Report
 
 
Review

Article Versions Notes

Cancers 2023, 15(24), 5751; https://doi.org/10.3390/cancers15245751
Action Date Notes Link
article xml file uploaded 8 December 2023 07:06 CET Original file -
article xml uploaded. 8 December 2023 07:06 CET Update -
article pdf uploaded. 8 December 2023 07:06 CET Version of Record https://www.mdpi.com/2072-6694/15/24/5751/pdf-vor
article html file updated 8 December 2023 07:07 CET Original file -
article xml file uploaded 13 December 2023 06:41 CET Update -
article xml uploaded. 13 December 2023 06:41 CET Update https://www.mdpi.com/2072-6694/15/24/5751/xml
article pdf uploaded. 13 December 2023 06:41 CET Updated version of record https://www.mdpi.com/2072-6694/15/24/5751/pdf
article html file updated 13 December 2023 06:43 CET Update https://www.mdpi.com/2072-6694/15/24/5751/html
Back to TopTop